top of page
Search

Nanomerics CSO delivers keynote lecture at the Business of Science 2024 Conference

Manchester, United Kingdom May 22nd, 2024.  Nanomerics Ltd., a private speciality pharmaceutical company today announced that Professor Ijeoma F. Uchegbu, Nanomerics’ Chief Scientific Officer delivered a keynote lecture at the Business of Science Conference.  The conference was held at the University of Salford in Greater Manchester, UK and was preceded by a glittering awards ceremony and dinner at the iconic Lowry Hotel in Salford.   In 2023, Uchegbu was awarded the Business of Science Special Recognition Award for leadership in business and science (https://www.businessofscience.co.uk/leadership-awards/). 



During the keynote lecture, Uchegbu spoke about her pioneering work in the area of the medicines design.  She spoke of the nanotechnology developed in her laboratory that reliably controls drug transport in vivo.    Work on the pharmaceutical use of Nanomerics’ Molecular Envelope Technology (MET) as a non-irritant ocular penetration enhancer was showcased in the lecture as was the ability of Nanomerics’ MET to deliver drugs to the retina using eye drops.  Nanomerics’ MET enables the efficient delivery of drugs to the front and back of the eye using transparent and oil-free eye drops.  Nanomerics’ MET has been used to formulate eye drops such as: OC134, indicated for severe allergic eye disease and OC137, indicated for the treatment of retinal diseases.   

Nanomerics is currently executing an OC134 Phase I clinical trial project.  The conclusion of  trial will transform the company to a clinical stage company and enable Nanomerics’ MET to be used to formulate a variety of ophthalmic active pharmaceutical ingredients.  Positive results from this clinical study will allow the company to fully exploit Nanomerics’ MET and deliver the potential benefits of this technology to patients with ocular conditions.  Nanomerics has a pipeline of ophthalmic medicine candidates.   

Nanomerics’ MET also underpins a number of Nanomerics’ central nervous system assets.  Noteworthy among these is Envelta™, a nasal spray powder, which is being developed as a pain therapeutic.  Envelta™ has been out-licensed by Nanomerics to Virpax Pharmaceuticals (NASDAQ:VRPX).  Envelta™ is being developed by Virpax Pharmaceuticals in collaboration with the US National Institutes of Health (NIH).  Nanomerics also has other collaborations with companies aiming to develop new medicines using its MET.   

Nanomerics is based in  state of the art laboratories in North London.  Nanomerics’ Chief Scientific Officer, Professor Ijeoma F. Uchegbu, says, “it was an honour and a privilege to be asked to give a keynote lecture at the Business of Science 2024 Conference and I thank the Business of Science community for all the work they are doing to showcase UK science innovation.”  

About Nanomerics 

Nanomerics Ltd is a speciality pharmaceutical company based in London, UK.  Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications.  Nanomerics’ proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science.  For example, the company’s Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists, Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include the eye drops: OC134 for the treatment of moderate to severe allergic conjunctivitis and OC137 for the treatment of retinal diseases. Additionally, a number of pharmaceutical product candidates have already been out-licensed by Nanomerics to Virpax Pharmaceuticals (NASDAQ:VRPX), e.g.  Envelta™, which is being developed as a pain therapeutic and NobrXiol™, in development for the treatment of epilepsy.  For more information, please visit www.nanomerics.com 

 

About Business of Science Conference 

The Business of Science Conference is an annual event which showcases science innovation and recognises leadership in the science innovation sector.  The event regularly attracts over 200 delegates from all sectors of the economy, including small and large business leaders, academics and representatives from government.  For more information, please visit https://www.businessofscience.co.uk/ 

 

Forward-Looking Statements 

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Nanomerics cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Forward-looking statements reflect our analysis only on their stated date, and Nanomerics takes no obligation to update or revise these statements except as may be required by law. 

 

Comments


bottom of page